Oil-in-Water Emulsion Adjuvant Reducing Reactogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine and immunogenic compositions face challenges in achieving a suitable immune response while minimizing reactogenicity, as existing oil-in-water emulsion adjuvants often require higher component concentrations.
Innovation Solution
The development of an immunogenic composition using an oil-in-water emulsion adjuvant with reduced amounts of squalene, tocopherol, and emulsifying agent, specifically 1 to 6 mg squalene, 1 to 7 mg tocopherol, and 0.4 to 3 mg emulsifying agent per human dose, maintaining immunogenicity while reducing reactogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher component concentrations are used in oil-in-water emulsion adjuvants, then immunogenicity is improved, but reactogenicity increases
Solution Approach 1:
The patent applies parameter changes by reducing the concentration of adjuvant components (squalene, tocopherol, emulsifying agent) to lower reactogenicity while maintaining immunogenicity through optimized formulation parameters and ratio relationships between components
2Object-affected harmful factors
If lower component concentrations are used in oil-in-water emulsion adjuvants, then reactogenicity is reduced, but immunogenicity decreases
Solution Approach 1:
The patent uses composite materials by formulating a multi-component oil-in-water emulsion system where squalene, tocopherol, and emulsifying agent work synergistically to maintain immunogenicity at reduced concentrations through their combined effects rather than relying on high doses of single components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This composition effectively elicits a comparable immune response to traditional formulations with lower component concentrations, thereby reducing adverse reactions in the host.
Implementation Method 1
an adjuvant consisting of an oil-in-water emulsion, wherein said oil-in-water emulsion comprises 1 to 6 mg squalene, 1 to 7 mg tocol and 0.4 to 3 mg emulsifying agent, per human dose
Data Source
Figure 1~2
Figure 3~4
Figure 5~5B
AI summary
The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5 - 10 mg metabolisable oil, 0.5 - 11 mg tocol and 0.1 - 4 mg emulsifying agent, per human dose.